Safety and efficacy of zanubrutinib in waldenstrom macroglobulinemia patients treated in common clinical practice: A retrospective-prospective study by fondazione italiana linfomi (FIL)
Retrospective-prospective study shows safety and effectiveness of zanubrutinib in waldenström macroglobulinemia patients, highlighting adverse events and treatment outcomes.
Key Points
Over 89% of patients remained on zanubrutinib treatment after 12 months, indicating safety and adherence.
The overall response rate was 89.7%, with a progression-free survival of 92% after treatment with zanubrutinib.
Retrospective-prospective study evaluated treatment management, safety, and outcomes in waldenström macroglobulinemia patients.
The findings suggest zanubrutinib has a favorable safety profile in a cohort with substantial comorbidities and age factors.